Symbols / SBFM Stock $2.46 -4.28% Sunshine Biopharma, Inc.
SBFM (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteSunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-08 | reit | Aegis Capital | Buy → Buy | $7 |
| 2024-12-05 | reit | Aegis Capital | Buy → Buy | $15 |
| 2023-08-07 | init | Aegis Capital | — → Buy | $3 |
- Oncology and antiviral drug maker Sunshine Biopharma plans $6M raise - Stock Titan Mon, 18 May 2026 07
- SBFM Stock Jumps As Sunshine Biopharma Secures New Drug Approvals - StocksToTrade ue, 02 Jun 2026 16
- Why Sunshine Biopharma (SBFM) Stock Dropped After Hours Today - Benzinga Fri, 29 May 2026 06
- Trending Stocks Today | Sunshine Biopharma Surges 568.77% - Moomoo Mon, 18 May 2026 07
- Sunshine Biopharma (SBFM) Gains Approval for Generic Rivaroxaban in Canada - GuruFocus Mon, 01 Jun 2026 19
- Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering - Yahoo Finance Mon, 18 May 2026 07
- Generic Xarelto pill from Sunshine Biopharma wins Canada approval - Stock Titan Mon, 01 Jun 2026 12
- Sunshine Biopharma (SBFM) rockets higher as traders focus on low-float dynamics after recent SEC financing filings - Quiver Quantitative Mon, 18 May 2026 07
- $Sunshine Biopharma (SBFM.US)$ :( - Moomoo Wed, 03 Jun 2026 02
- Sunshine Biopharma raises $6M selling 12M units at $0.50 - Stock Titan ue, 19 May 2026 07
- Sunshine Biopharma to cut shares from 21M to 2.1M via June 1 reverse split - Stock Titan hu, 28 May 2026 07
- Sunshine Biopharma (SBFM) Q1 2026 results show lower revenue but steady losses - Stock Titan Wed, 13 May 2026 07
- Canada clears generic Amoxicillin, widening treatment choices - Stock Titan hu, 21 May 2026 07
- New coronavirus patent aims to keep treatments working as virus mutates - Stock Titan Fri, 29 May 2026 12
- Sunshine Biopharma (NASDAQ: SBFM) plans $6M unit and warrant sale - Stock Titan ue, 12 May 2026 07
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
36.31
+4.11%
|
34.87
+44.75%
|
24.09
+454.42%
|
4.35
|
| Operating Revenue |
|
36.31
+4.11%
|
34.87
+44.75%
|
24.09
+454.42%
|
4.35
|
| Cost Of Revenue |
|
24.05
-0.64%
|
24.20
+53.64%
|
15.75
+494.69%
|
2.65
|
| Reconciled Cost Of Revenue |
|
24.05
-0.64%
|
24.20
+53.64%
|
15.75
+494.69%
|
2.65
|
| Gross Profit |
|
12.26
+14.86%
|
10.67
+27.95%
|
8.34
+391.53%
|
1.70
|
| Operating Expense |
|
16.73
+1.53%
|
16.48
+25.58%
|
13.12
+26.55%
|
10.37
|
| Research And Development |
|
0.60
-35.29%
|
0.93
-49.68%
|
1.86
+128.59%
|
0.81
|
| Selling General And Administration |
|
15.33
+2.62%
|
14.94
+37.93%
|
10.83
+14.26%
|
9.48
|
| Selling And Marketing Expense |
|
1.14
+21.66%
|
0.94
+28.06%
|
0.73
+27.01%
|
0.58
|
| General And Administrative Expense |
|
14.18
+1.34%
|
14.00
+38.65%
|
10.10
+13.43%
|
8.90
|
| Salaries And Wages |
|
7.67
-5.58%
|
8.12
+32.81%
|
6.11
-3.81%
|
6.35
|
| Other Gand A |
|
6.52
+10.90%
|
5.88
+47.61%
|
3.98
+56.47%
|
2.55
|
| Total Expenses |
|
40.78
+0.24%
|
40.69
+40.89%
|
28.88
+121.80%
|
13.02
|
| Operating Income |
|
-4.48
+22.94%
|
-5.81
-21.46%
|
-4.79
+44.83%
|
-8.67
|
| Total Operating Income As Reported |
|
-6.23
-7.14%
|
-5.81
-21.46%
|
-4.79
+82.28%
|
-27.00
|
| EBITDA |
|
-5.62
-9.44%
|
-5.14
-34.31%
|
-3.82
+85.54%
|
-26.45
|
| Normalized EBITDA |
|
-3.87
+24.09%
|
-5.09
-33.17%
|
-3.82
+52.96%
|
-8.13
|
| Reconciled Depreciation |
|
0.33
+48.56%
|
0.22
+49.87%
|
0.15
+492.72%
|
0.03
|
| EBIT |
|
-5.95
-11.07%
|
-5.36
-34.90%
|
-3.97
+84.99%
|
-26.47
|
| Total Unusual Items |
|
-1.76
-3883.17%
|
-0.04
-17892.65%
|
-0.00
+100.00%
|
-18.32
|
| Total Unusual Items Excluding Goodwill |
|
-1.76
-3883.17%
|
-0.04
-17892.65%
|
-0.00
+100.00%
|
-18.32
|
| Special Income Charges |
|
-1.76
|
0.00
|
0.00
+100.00%
|
-18.32
|
| Other Special Charges |
|
—
|
—
|
—
|
-0.01
|
| Impairment Of Capital Assets |
|
1.75
|
0.00
|
0.00
-100.00%
|
18.33
|
| Net Income |
|
-5.98
-16.39%
|
-5.13
-13.94%
|
-4.51
+83.15%
|
-26.74
|
| Pretax Income |
|
-5.95
-10.89%
|
-5.37
-30.60%
|
-4.11
+84.49%
|
-26.51
|
| Net Non Operating Interest Income Expense |
|
0.28
-42.35%
|
0.49
-27.78%
|
0.67
+40.78%
|
0.48
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
0.01
-93.61%
|
0.14
+248.39%
|
0.04
|
| Net Interest Income |
|
0.28
-42.35%
|
0.49
-27.78%
|
0.67
+40.78%
|
0.48
|
| Interest Expense |
|
0.00
-100.00%
|
0.01
-93.61%
|
0.14
+248.39%
|
0.04
|
| Interest Income Non Operating |
|
0.28
-43.37%
|
0.50
-38.91%
|
0.81
+56.56%
|
0.52
|
| Interest Income |
|
0.28
-43.37%
|
0.50
-38.91%
|
0.81
+56.56%
|
0.52
|
| Other Income Expense |
|
-1.76
-3883.17%
|
-0.04
-17892.65%
|
-0.00
+100.00%
|
-18.32
|
| Gain On Sale Of Security |
|
0.00
+105.99%
|
-0.04
-17892.65%
|
-0.00
+48.53%
|
-0.00
|
| Tax Provision |
|
0.02
+109.20%
|
-0.23
-159.43%
|
0.40
+69.38%
|
0.23
|
| Tax Rate For Calcs |
|
0.00
+380.55%
|
0.00
-79.19%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.37
-19041.10%
|
-0.00
-3644.19%
|
-0.00
+100.00%
|
-3.85
|
| Net Income Including Noncontrolling Interests |
|
-5.98
-16.39%
|
-5.13
-13.94%
|
-4.51
+83.15%
|
-26.74
|
| Net Income From Continuing Operation Net Minority Interest |
|
-5.98
-16.39%
|
-5.13
-13.94%
|
-4.51
+83.15%
|
-26.74
|
| Net Income From Continuing And Discontinued Operation |
|
-5.98
-16.39%
|
-5.13
-13.94%
|
-4.51
+83.15%
|
-26.74
|
| Net Income Continuous Operations |
|
-5.98
-16.39%
|
-5.13
-13.94%
|
-4.51
+83.15%
|
-26.74
|
| Normalized Income |
|
-4.59
+9.89%
|
-5.09
-13.01%
|
-4.51
+63.29%
|
-12.27
|
| Net Income Common Stockholders |
|
-5.98
-16.39%
|
-5.13
-13.94%
|
-4.51
+83.15%
|
-26.74
|
| Diluted EPS |
|
-14.40
+80.33%
|
-73.20
+97.92%
|
-3,513.60
+85.17%
|
-23,688.61
|
| Basic EPS |
|
-14.40
+80.33%
|
-73.20
+97.92%
|
-3,513.60
+85.17%
|
-23,688.61
|
| Basic Average Shares |
|
0.42
+492.40%
|
0.07
+5373.79%
|
0.00
+13.55%
|
0.00
|
| Diluted Average Shares |
|
0.42
+492.40%
|
0.07
+5373.79%
|
0.00
+13.55%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-5.98
-16.39%
|
-5.13
-13.94%
|
-4.51
+83.15%
|
-26.74
|
| Depreciation Amortization Depletion Income Statement |
|
0.33
+48.56%
|
0.22
+49.87%
|
0.15
+492.72%
|
0.03
|
| Depreciation And Amortization In Income Statement |
|
0.33
+48.56%
|
0.22
+49.87%
|
0.15
+492.72%
|
0.03
|
| Depreciation Income Statement |
|
—
|
—
|
—
|
—
|
| Gain On Sale Of PPE |
|
-0.01
|
0.00
|
—
|
—
|
| Other Taxes |
|
0.47
+21.27%
|
0.39
+33.57%
|
0.29
+424.57%
|
0.06
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
30.08
-1.57%
|
30.56
+11.75%
|
27.35
-6.49%
|
29.24
|
| Current Assets |
|
26.85
+3.42%
|
25.97
+4.32%
|
24.89
-8.87%
|
27.31
|
| Cash Cash Equivalents And Short Term Investments |
|
9.12
-5.81%
|
9.69
-40.55%
|
16.29
-25.35%
|
21.83
|
| Cash And Cash Equivalents |
|
9.12
-5.81%
|
9.69
-40.55%
|
16.29
-25.35%
|
21.83
|
| Cash Financial |
|
9.12
-5.81%
|
9.69
-40.55%
|
16.29
-25.35%
|
21.83
|
| Receivables |
|
3.46
-10.56%
|
3.87
+51.56%
|
2.55
+33.48%
|
1.91
|
| Accounts Receivable |
|
3.46
-10.56%
|
3.87
+51.56%
|
2.55
+33.48%
|
1.91
|
| Inventory |
|
13.47
+19.45%
|
11.28
+96.66%
|
5.73
+74.31%
|
3.29
|
| Finished Goods |
|
13.47
+19.45%
|
11.28
+96.66%
|
5.73
|
—
|
| Prepaid Assets |
|
0.80
-29.55%
|
1.13
+264.88%
|
0.31
+9.44%
|
0.28
|
| Total Non Current Assets |
|
3.21
-30.22%
|
4.59
+86.98%
|
2.46
+27.20%
|
1.93
|
| Net PPE |
|
1.32
-11.19%
|
1.48
+46.36%
|
1.01
-12.30%
|
1.15
|
| Gross PPE |
|
1.83
+0.58%
|
1.82
+51.22%
|
1.20
-2.89%
|
1.24
|
| Accumulated Depreciation |
|
-0.51
-52.40%
|
-0.34
-77.13%
|
-0.19
-126.71%
|
-0.08
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.78
-16.79%
|
0.94
+44.72%
|
0.65
|
—
|
| Machinery Furniture Equipment |
|
0.62
+36.00%
|
0.46
+24.86%
|
0.37
+16.11%
|
0.32
|
| Other Properties |
|
0.34
-0.42%
|
0.34
+96.02%
|
0.17
-81.38%
|
0.92
|
| Leases |
|
0.09
+4.98%
|
0.09
+399.92%
|
0.02
|
0.00
|
| Goodwill And Other Intangible Assets |
|
1.89
-37.43%
|
3.02
+109.08%
|
1.44
+85.91%
|
0.78
|
| Non Current Deferred Assets |
|
0.00
-100.00%
|
0.09
|
0.00
|
—
|
| Non Current Deferred Taxes Assets |
|
0.00
-100.00%
|
0.09
|
0.00
|
—
|
| Total Liabilities Net Minority Interest |
|
7.04
-0.27%
|
7.06
+14.99%
|
6.14
-19.39%
|
7.62
|
| Current Liabilities |
|
6.44
+2.04%
|
6.31
+13.74%
|
5.55
-19.90%
|
6.93
|
| Payables And Accrued Expenses |
|
6.23
+1.98%
|
6.11
+12.41%
|
5.43
-20.19%
|
6.81
|
| Payables |
|
6.23
+1.98%
|
6.11
+12.41%
|
5.43
-20.19%
|
6.81
|
| Accounts Payable |
|
5.66
+2.19%
|
5.54
+114.39%
|
2.59
-7.75%
|
2.80
|
| Other Payable |
|
0.30
+0.00%
|
0.30
-88.39%
|
2.55
-29.85%
|
3.63
|
| Current Accrued Expenses |
|
—
|
—
|
—
|
0.00
|
| Total Tax Payable |
|
0.27
+0.00%
|
0.27
-10.54%
|
0.30
-19.65%
|
0.37
|
| Income Tax Payable |
|
0.27
+0.00%
|
0.27
-10.54%
|
0.30
-19.65%
|
0.37
|
| Current Debt And Capital Lease Obligation |
|
0.22
+3.79%
|
0.21
+75.07%
|
0.12
-3.54%
|
0.12
|
| Current Debt |
|
—
|
—
|
—
|
3.63
|
| Other Current Borrowings |
|
—
|
—
|
—
|
3.63
|
| Current Capital Lease Obligation |
|
0.22
+3.79%
|
0.21
+75.07%
|
0.12
-3.54%
|
0.12
|
| Other Current Liabilities |
|
—
|
—
|
—
|
0.12
|
| Total Non Current Liabilities Net Minority Interest |
|
0.60
-19.86%
|
0.74
+26.70%
|
0.59
-14.23%
|
0.69
|
| Long Term Debt And Capital Lease Obligation |
|
0.60
-19.86%
|
0.74
+38.16%
|
0.54
-16.07%
|
0.64
|
| Long Term Debt |
|
—
|
—
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
0.60
-19.86%
|
0.74
+38.16%
|
0.54
-16.07%
|
0.64
|
| Non Current Deferred Liabilities |
|
—
|
0.00
-100.00%
|
0.05
+13.24%
|
0.04
|
| Non Current Deferred Taxes Liabilities |
|
—
|
0.00
-100.00%
|
0.05
+13.24%
|
0.04
|
| Stockholders Equity |
|
23.04
-1.97%
|
23.50
+10.81%
|
21.21
-1.94%
|
21.63
|
| Common Stock Equity |
|
23.03
-1.97%
|
23.49
+10.76%
|
21.21
-1.94%
|
21.63
|
| Capital Stock |
|
0.02
+14.92%
|
0.02
+1436.49%
|
0.00
-95.70%
|
0.02
|
| Common Stock |
|
0.00
+90.12%
|
0.00
+18328.57%
|
0.00
-99.94%
|
0.02
|
| Preferred Stock |
|
0.01
+0.00%
|
0.01
+1200.00%
|
0.00
+0.00%
|
0.00
|
| Share Issued |
|
0.49
+90.15%
|
0.26
+18316.06%
|
0.00
+24.09%
|
0.00
|
| Ordinary Shares Number |
|
0.49
+90.15%
|
0.26
+18316.06%
|
0.00
+24.09%
|
0.00
|
| Additional Paid In Capital |
|
98.10
+5.08%
|
93.35
+10.59%
|
84.42
+4.42%
|
80.84
|
| Retained Earnings |
|
-75.02
-8.65%
|
-69.04
-8.03%
|
-63.91
-7.59%
|
-59.40
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.07
+92.13%
|
-0.83
-219.23%
|
0.70
+330.10%
|
0.16
|
| Other Equity Adjustments |
|
-0.07
+92.13%
|
-0.83
-219.23%
|
0.70
+330.10%
|
0.16
|
| Total Equity Gross Minority Interest |
|
23.04
-1.97%
|
23.50
+10.81%
|
21.21
-1.94%
|
21.63
|
| Total Capitalization |
|
23.04
-1.97%
|
23.50
+10.81%
|
21.21
-1.94%
|
21.63
|
| Working Capital |
|
20.41
+3.86%
|
19.65
+1.62%
|
19.34
-5.12%
|
20.38
|
| Invested Capital |
|
23.03
-1.97%
|
23.49
+10.76%
|
21.21
-1.94%
|
21.63
|
| Total Debt |
|
0.81
-14.70%
|
0.95
+44.82%
|
0.66
-14.05%
|
0.77
|
| Capital Lease Obligations |
|
0.81
-14.70%
|
0.95
+44.82%
|
0.66
-14.05%
|
0.77
|
| Net Tangible Assets |
|
21.15
+3.26%
|
20.48
+3.63%
|
19.76
-5.22%
|
20.85
|
| Tangible Book Value |
|
21.14
+3.26%
|
20.47
+3.57%
|
19.76
-5.22%
|
20.85
|
| Current Notes Payable |
|
—
|
—
|
—
|
—
|
| Interest Payable |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Equity |
|
0.01
+0.00%
|
0.01
+1200.00%
|
0.00
+0.00%
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-5.33
+57.44%
|
-12.52
-42.73%
|
-8.78
-67.20%
|
-5.25
|
| Cash Flow From Continuing Operating Activities |
|
-5.33
+57.44%
|
-12.52
-42.73%
|
-8.78
-67.20%
|
-5.25
|
| Net Income From Continuing Operations |
|
-5.98
-16.39%
|
-5.13
-13.94%
|
-4.51
+83.15%
|
-26.74
|
| Depreciation Amortization Depletion |
|
0.33
+48.56%
|
0.22
+49.87%
|
0.15
+492.72%
|
0.03
|
| Depreciation |
|
—
|
0.15
+32.35%
|
0.11
|
—
|
| Amortization Cash Flow |
|
—
|
0.08
+100.30%
|
0.04
|
—
|
| Depreciation And Amortization |
|
0.33
+48.56%
|
0.22
+49.87%
|
0.15
+492.72%
|
0.03
|
| Amortization Of Intangibles |
|
—
|
0.08
+100.30%
|
0.04
|
—
|
| Other Non Cash Items |
|
—
|
-2.24
|
—
|
-0.01
|
| Asset Impairment Charge |
|
1.75
|
0.00
|
0.00
-100.00%
|
18.33
|
| Deferred Tax |
|
—
|
0.00
|
0.00
|
—
|
| Deferred Income Tax |
|
—
|
0.00
|
0.00
|
—
|
| Operating Gains Losses |
|
0.01
|
—
|
—
|
0.00
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Gain Loss On Sale Of PPE |
|
0.01
|
0.00
|
—
|
—
|
| Change In Working Capital |
|
-1.45
+73.09%
|
-5.37
-21.64%
|
-4.42
-240.06%
|
3.15
|
| Change In Receivables |
|
-0.12
+95.03%
|
-2.34
-293.54%
|
-0.59
-13.28%
|
-0.52
|
| Changes In Account Receivables |
|
-0.12
+95.03%
|
-2.34
-293.54%
|
-0.59
-13.28%
|
-0.52
|
| Change In Inventory |
|
-1.64
+72.74%
|
-6.01
-153.93%
|
-2.37
-5603.45%
|
0.04
|
| Change In Prepaid Assets |
|
0.48
+332.08%
|
-0.21
-879.84%
|
-0.02
-125.52%
|
0.08
|
| Change In Payables And Accrued Expense |
|
-0.19
-105.99%
|
3.17
+320.66%
|
-1.44
-140.45%
|
3.55
|
| Change In Accrued Expense |
|
—
|
—
|
0.00
+100.00%
|
-0.05
|
| Change In Payable |
|
-0.19
-105.99%
|
3.17
+320.66%
|
-1.44
-139.91%
|
3.60
|
| Change In Account Payable |
|
-0.19
-104.77%
|
3.98
+392.04%
|
-1.36
-140.61%
|
3.36
|
| Change In Other Current Assets |
|
0.20
+159.68%
|
-0.34
|
—
|
—
|
| Change In Other Current Liabilities |
|
-0.19
-153.90%
|
0.35
|
—
|
—
|
| Investing Cash Flow |
|
-0.84
+57.75%
|
-1.98
-201.66%
|
-0.66
+95.51%
|
-14.62
|
| Cash Flow From Continuing Investing Activities |
|
-0.84
+57.75%
|
-1.98
-201.66%
|
-0.66
+95.51%
|
-14.62
|
| Cash From Discontinued Investing Activities |
|
—
|
—
|
—
|
—
|
| Net PPE Purchase And Sale |
|
-0.17
+89.47%
|
-1.66
-3434.25%
|
0.05
+130.94%
|
-0.16
|
| Purchase Of PPE |
|
-0.17
+89.47%
|
-1.66
-1914.63%
|
-0.08
+57.60%
|
-0.19
|
| Sale Of PPE |
|
—
|
—
|
0.13
+295.31%
|
0.03
|
| Capital Expenditure |
|
-0.84
+57.75%
|
-1.98
-151.15%
|
-0.79
-158.40%
|
-0.30
|
| Net Business Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-14.35
|
| Purchase Of Business |
|
—
|
—
|
0.00
+100.00%
|
-14.35
|
| Net Intangibles Purchase And Sale |
|
-0.66
-105.37%
|
-0.32
+54.34%
|
-0.71
-535.81%
|
-0.11
|
| Purchase Of Intangibles |
|
-0.66
-105.37%
|
-0.32
+54.34%
|
-0.71
-535.81%
|
-0.11
|
| Financing Cash Flow |
|
4.75
-46.90%
|
8.94
+161.02%
|
3.43
-91.32%
|
39.47
|
| Cash Flow From Continuing Financing Activities |
|
4.75
-46.90%
|
8.94
+161.02%
|
3.43
-91.32%
|
39.47
|
| Net Issuance Payments Of Debt |
|
—
|
0.35
+376.16%
|
-0.13
+93.48%
|
-1.93
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-1.90
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-1.90
|
| Net Long Term Debt Issuance |
|
—
|
0.35
+376.16%
|
-0.13
+93.48%
|
-1.93
|
| Net Common Stock Issuance |
|
1.83
-66.03%
|
5.38
+51.71%
|
3.55
-88.28%
|
30.27
|
| Common Stock Payments |
|
0.00
+100.00%
|
-3.14
-480.19%
|
-0.54
-446.61%
|
-0.10
|
| Repurchase Of Capital Stock |
|
0.00
+100.00%
|
-3.14
-480.19%
|
-0.54
-446.61%
|
-0.10
|
| Proceeds From Stock Option Exercised |
|
2.92
-17.96%
|
3.56
+101522.27%
|
0.00
-99.97%
|
13.19
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
-2.06
|
| Changes In Cash |
|
-1.42
+74.49%
|
-5.56
+7.38%
|
-6.01
-130.65%
|
19.60
|
| Effect Of Exchange Rate Changes |
|
0.86
+182.02%
|
-1.04
-321.23%
|
0.47
+156.42%
|
0.18
|
| Beginning Cash Position |
|
9.69
-40.55%
|
16.29
-25.35%
|
21.83
+967.22%
|
2.05
|
| End Cash Position |
|
9.12
-5.81%
|
9.69
-40.55%
|
16.29
-25.35%
|
21.83
|
| Free Cash Flow |
|
-6.17
+57.48%
|
-14.50
-51.67%
|
-9.56
-72.21%
|
-5.55
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.01
|
0.00
-100.00%
|
0.05
|
| Income Tax Paid Supplemental Data |
|
0.00
-100.00%
|
0.58
|
0.00
|
0.00
|
| Change In Income Tax Payable |
|
0.00
+100.00%
|
-0.81
-1008.69%
|
-0.07
-130.23%
|
0.24
|
| Change In Interest Payable |
|
—
|
—
|
0.00
+100.00%
|
-0.05
|
| Change In Tax Payable |
|
0.00
+100.00%
|
-0.81
-1008.69%
|
-0.07
-130.23%
|
0.24
|
| Common Stock Issuance |
|
1.83
-78.54%
|
8.52
+108.41%
|
4.09
-86.53%
|
30.37
|
| Issuance Of Capital Stock |
|
1.83
-78.54%
|
8.52
+108.41%
|
4.09
-86.53%
|
30.37
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
-0.10
|
| Preferred Stock Payments |
|
—
|
—
|
—
|
-0.10
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-05-29 View
- 8-K2026-05-19 View
- 10-Q2026-05-13 View
- 42026-04-14 View
- 8-K2026-04-09 View
- 10-K2026-04-03 View
- 8-K2026-03-09 View
- 8-K2026-02-20 View
- 8-K2026-02-05 View
- 8-K2025-12-12 View
- 10-Q2025-11-13 View
- 8-K2025-09-30 View
- 10-Q2025-08-12 View
- 8-K2025-05-19 View
- 10-Q2025-05-15 View
- 8-K2025-04-03 View
- 8-K2025-04-02 View
- 10-K2025-04-01 View
- 8-K2025-01-15 View
- 8-K2024-12-10 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|